Cristina Aquino

Geopolitical tensions are likely to drive oil prices higher at the start of the trading week, as oil has been reacting to supply concerns and risk aversion.

During times of market turmoil, investors tend to flock to big tech companies because they are large, cash-rich, and unlikely to go bust, making them a relative safe haven.

Domino's Pizza (DPZ) reported a larger-than-expected rise in comparable sales, driven by "budget-friendly pies" and promotions. Stock finished up ~4%. In an environment where consumers are stretched (inflation/economy fears), they trade down to the lowest cost calorie options. DPZ is the primary beneficiary of the "trade-down" effect in food. LONG. A defensive play on the consumer wallet. Commodity costs (cheese/dough) rising could squeeze margins despite volume growth.

Novo Nordisk's (NVO) next-gen obesity shot fell short of Eli Lilly's (LLY) rival drug in data released today. Additionally, the FDA approved a label expansion for LLY's Zepbound. The GLP-1 market is a duopoly, but momentum is shifting. LLY is demonstrating clinical superiority and regulatory wins, while NVO is hitting pipeline stumbles. Capital will rotate from the loser to the winner within the sector. LONG LLY / SHORT NVO. LLY is solidifying dominance. NVO could release better data on other pipeline candidates; supply constraints could cap LLY's near-term upside.

Novo Nordisk's (NVO) next-gen obesity shot fell short of Eli Lilly's (LLY) rival drug in data released today. Additionally, the FDA approved a label expansion for LLY's Zepbound. The GLP-1 market is a duopoly, but momentum is shifting. LLY is demonstrating clinical superiority and regulatory wins, while NVO is hitting pipeline stumbles. Capital will rotate from the loser to the winner within the sector. LONG LLY / SHORT NVO. LLY is solidifying dominance. NVO could release better data on other pipeline candidates; supply constraints could cap LLY's near-term upside.